Eterna Therapeutics Inc. (ERNA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
1035 CAMBRIDGE STREET CAMBRIDGE, MA 02141 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,729 | 7,575 | 11,446 | 16,985 | 777 | 3,209 | |||
| Cash and cash equivalent | 1,729 | 7,575 | 11,446 | 16,985 | 777 | 3,209 | |||
| Restricted cash and investments | 50 | ||||||||
| Receivables | 437 | 425 | 951 | 684 | 116 | 1,195 | |||
| Deferred costs | 72 | 274 | |||||||
| Other undisclosed current assets | 186 | 1,599 | 1,284 | 1,097 | 759 | 1,342 | |||
| Total current assets: | 2,352 | 9,599 | 13,681 | 18,766 | 1,724 | 6,070 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 20 | 41 | |||||||
| Operating lease, right-of-use asset | 670 | 32,781 | 1,030 | 2,567 | 36 | 2,101 | |||
| Property, plant and equipment | 85 | 493 | 236 | 670 | 502 | 2,822 | |||
| Long-term investments and receivables | 59 | 1,000 | |||||||
| Long-term investments | 59 | 1,000 | |||||||
| Intangible assets, net (including goodwill) | 2,044 | 2,044 | 2,044 | 8,904 | 1,392 | ||||
| Goodwill | 2,044 | 2,044 | 2,044 | 2,044 | 696 | ||||
| Intangible assets, net (excluding goodwill) | 6,860 | 696 | |||||||
| Regulated entity, other noncurrent assets | 11 | ||||||||
| Restricted cash and investments | 4,095 | 4,095 | 150 | ||||||
| Deferred costs | 72 | 274 | |||||||
| Other noncurrent assets | 118 | 120 | 1,134 | 50 | 97 | ||||
| Other undisclosed noncurrent assets | 522 | 1,341 | 1,167 | ||||||
| Total noncurrent assets: | 2,917 | 39,533 | 8,598 | 13,663 | 2,021 | 8,055 | |||
| TOTAL ASSETS: | 5,269 | 49,132 | 22,279 | 32,429 | 3,745 | 14,125 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,728 | 2,960 | 5,246 | 3,004 | 587 | 2,047 | |||
| Taxes payable | ✕ | ✕ | ✕ | ✕ | 15 | 134 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 64 | 588 | |||
| Accounts payable | 1,721 | 1,067 | 1,620 | 1,755 | 270 | 835 | |||
| Accrued liabilities | 1,007 | 1,893 | 3,626 | 1,249 | 238 | 490 | |||
| Deferred revenue | 190 | 76 | 460 | ||||||
| Debt | 1,522 | 3,169 | |||||||
| Business combination, contingent consideration, liability | |||||||||
| Other liabilities | 363 | 247 | 139 | 419 | |||||
| Due to related parties | ✕ | ✕ | ✕ | 1,750 | |||||
| Other undisclosed current liabilities | 210 | 3,423 | 295 | 426 | 36 | ||||
| Total current liabilities: | 2,938 | 6,573 | 7,654 | 3,677 | 2,360 | 6,095 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 6,773 | 2,297 | 532 | 2,911 | |||||
| Long-term debt, excluding current maturities | 6,773 | 532 | |||||||
| Finance lease, liability | 20 | ||||||||
| Liabilities, other than long-term debt | 630 | 33,469 | 2,518 | 19,953 | 2 | 28 | |||
| Deferred revenue | 392 | 2 | 2 | ||||||
| Due to related parties | ✕ | ✕ | ✕ | 1,206 | |||||
| Other liabilities | 111 | 94 | 23 | 26 | |||||
| Operating lease, liability | 477 | 32,854 | 887 | 2,297 | 2,891 | ||||
| Business combination, contingent consideration, liability | 41 | 107 | 19,930 | ||||||
| Derivative instruments and hedges, liabilities | 1 | 116 | 331 | ||||||
| Other undisclosed noncurrent liabilities | 84 | ||||||||
| Total noncurrent liabilities: | 630 | 40,326 | 2,518 | 22,250 | 534 | 2,939 | |||
| Total liabilities: | 3,568 | 46,899 | 10,172 | 25,927 | 2,894 | 9,034 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 1,701 | 2,233 | 12,107 | 6,502 | 851 | 5,091 | |||
| Preferred stock | 1 | 1 | 1 | ||||||
| Common stock | 257 | 27 | 26 | 260 | 15 | 14 | |||
| Treasury stock, value | (456) | (456) | |||||||
| Additional paid in capital | 232,979 | 189,186 | 177,377 | 165,944 | 136,934 | 136,721 | |||
| Accumulated other comprehensive income | 245 | 268 | |||||||
| Accumulated deficit | (231,536) | (186,981) | (165,297) | (159,703) | (135,888) | (131,457) | |||
| Other undisclosed equity, attributable to parent | 1 | 1 | 1 | ||||||
| Total equity: | 1,701 | 2,233 | 12,107 | 6,502 | 851 | 5,091 | |||
| TOTAL LIABILITIES AND EQUITY: | 5,269 | 49,132 | 22,279 | 32,429 | 3,745 | 14,125 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 582 | 68 | 84 | 84 | 5,800 | 19,806 | ||
| Sublease income | 84 | 84 | 84 | 84 | ||||
| Other income | 100 | |||||||
| Cost of revenue | (96) | (236) | (1,538) | (2,517) | ||||
| Cost of product and service sold | (1,538) | (2,517) | ||||||
| Other undisclosed gross profit | ||||||||
| Gross profit: | 486 | (168) | 84 | 84 | 4,262 | 17,289 | ||
| Operating expenses | (16,160) | (20,967) | (33,217) | (113,552) | (12,109) | (21,568) | ||
| Other undisclosed operating income (loss) | (84) | (84) | 1,538 | 2,517 | ||||
| Operating loss: | (15,674) | (21,135) | (33,217) | (113,552) | (6,309) | (1,762) | ||
| Nonoperating income (expense) | (28,835) | (536) | 8,683 | (8,749) | 1,888 | (258) | ||
| Investment income, nonoperating | 249 | 138 | ||||||
| Other nonoperating income (expense) | 70 | (334) | (1,171) | 899 | 1,888 | (258) | ||
| Interest and debt expense | (6,500) | (614) | (14) | (9) | ||||
| Loss from continuing operations before equity method investments, income taxes: | (51,009) | (22,285) | (24,534) | (122,301) | (4,435) | (2,029) | ||
| Other undisclosed income from continuing operations before income taxes | 6,500 | 614 | 14 | 9 | ||||
| Loss from continuing operations before income taxes: | (44,509) | (21,671) | (24,534) | (122,301) | (4,421) | (2,020) | ||
| Income tax expense (benefit) | (30) | 3 | (45) | (5) | 6 | (27) | ||
| Loss from continuing operations: | (44,539) | (21,668) | (24,579) | (122,306) | (4,415) | (2,047) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (122,306) | (4,415) | (2,047) | |
| Net loss attributable to parent: | (44,539) | (21,668) | (24,579) | (122,306) | (4,415) | (2,047) | ||
| Preferred stock dividends and other adjustments | (16) | (16) | (16) | (16) | (16) | (16) | ||
| Net loss available to common stockholders, diluted: | (44,555) | (21,684) | (24,595) | (122,322) | (4,431) | (2,063) | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (44,539) | (21,668) | (24,579) | (122,306) | (4,415) | (2,047) | ||
| Comprehensive loss: | (44,539) | (21,668) | (24,579) | (122,306) | (4,415) | (2,047) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (23) | 68 | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (44,539) | (21,668) | (24,579) | (122,306) | (4,438) | (1,979) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.